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Remote ischemic conditioning (RIC) was first studied around 1993 when dogs that had intermittent canine left circumflex coronary artery occlusion before left anterior descending occlusion experienced decreased infarct size. 3 Later, this expanded to encompass cycles of inflation/ deflation of a sphygmomanometer placed around the upper (or lower) extremity before (preconditioning) or after (postconditioning) percutaneous coronary intervention (PCI). 4 RIC is most commonly performed by inflating a blood pressure cuff around the arm, typically for 3 or 5 minutes, and 1 to 4 cycles, with most contemporary studies using 4 5-minute cuff inflations. 1, 5 Given its simplicity, RIC could readily be initiated in an ambulance during transport for primary PCI in acute MI, or could be administered before a planned coronary revascularization with either PCI or coronary artery bypass graft surgery. Ischemic conditioning has been the focus of extensive investigative efforts: a PubMed search on "ischemic preconditioning" on September 8, 2018 provided 10 301 results. While many preclinical studies have shown benefit, clinical studies have provided less consistent results. 6 Remote ischemic preconditioning did not reduce the incidence of major adverse cardiac and cerebral events in 2 large randomized-controlled cardiac surgery trials, the RIPHeart (Remote Ischemic Preconditioning for Heart Surgery) trial 7 and the ERICCA (Effect of Remote Ischemic Preconditioning on Clinical Outcomes in Patients Undergoing Coronary Artery Bypass Surgery) trial. 7, 8 Although this might be related to use of propofol for sedation (which may diminish or abolish the effect of ischemia-induced cardioprotection), in ERICCA the incidence of cardiovascular death was numerically higher in the remote ischemic preconditioning group (P=0.08), suggesting possible harm. 8 Unlike cardiac surgery, there are no completed large randomized-controlled trials assessing the effect of RIC during PCI. RIC holds the most promise for treating MI patients, with small studies showing improved salvage index by nuclear imaging, reduced infarct size and edema by magnetic resonance imaging, and improved ST-segment elevation resolution and cardiac biomarker rise. 1 The ongoing 5413 patient CONDI2/ERIC-PPCI (Effect of Remote Ischaemic Conditioning on Clinical Outcomes in STEMI Patients Undergoing PPCI) trial is examining the impact of RIC on the 12-month incidence of cardiac death and hospitalization for heart failure, and results are anticipated in 2019.
In the setting of elective PCI, several relatively small studies such as the CRISP Stent (Cardiac Remote Ischemic Preconditioning in Coronary Stenting) study have shown that RIC can reduce the incidence of periprocedural MI, chest pain, ischemic ECG changes, and in at least 1 study, reduce the combined end point of all-cause mortality, nonfatal MI, transient ischemic attack or stroke, and heart failure hospitalizations. 1, 9 Other studies, however, were negative, with interpretation of conflicting data somewhat limited by interstudy differences in methodology and study populations. 10, 11 In this issue of the Journal of the American Heart Association (JAHA), Yong et al examined the impact of RIC on the coronary microcirculation, as assessed by the index of microcirculatory resistance, coronary flow reserve, and hyperemic transit time. 12 In a carefully designed study, they randomized 30 patients with stable coronary artery disease, undergoing
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fractional 14 While studies such as that of Yong et al 12 are improving our insight into the mechanisms underlying the impact of RIC, applying this therapy with the intent of improving the outcomes of PCI for patients with stable coronary artery disease will likely face significant hurdles for implementation: the incidence of periprocedural MI, as assessed by cardiac biomarker elevation, is relatively infrequent in this group, and has not consistently been linked with higher risk for subsequent major adverse clinical events. 15 Hence, even if RIC reduced the incidence of periprocedural myocardial infarction in patients with stable coronary artery disease, it is unclear whether this would translate into better long-term clinical outcomes. Deciding on whether to apply a medical intervention should always be based on the risk/benefit ratio, as well as its costeffectiveness. The major appeal of RIC has been its low risk (although there were some concerns with higher cardiovascular mortality in the ERICCA trial as described above 8 ), low cost, and ease of implementation. Whether RIC provides clinical benefit during PCI remains controversial and may be hard to prove in low-risk patients with stable coronary artery disease. Patients presenting with MI may have more to gain, but whether the study findings will also apply to those patients is unknown: "pre"conditioning cannot be performed in such patients and the microcirculation may be irreversibly injured by the time RIC is initiated. Also mechanical means, such as embolic protection devices, may be more efficacious in protecting the coronary microcirculation from additional damage, as shown in the VAMPIRE (Vacuum Aspiration Thrombus Removal) 3 trial. 16 On the other hand, with increasing data supporting the use of multivessel revascularization during ST-segment-elevation myocardial infarction, there may be opportunity for preventing injury caused by distal embolization or side branch compromise of those initially "unharmed" myocardial territories. "Waiting for Godot" describes the current status of the field of cardioprotection. Whether CONDI2/ERIC-PPCI will bring Godot remains to be seen.
